MICROSER 8 mg. 50 tablets

MICROSER 8 mg. 50 tablets
€ 15.00
Add to Cart
Symptomatic treatment of pathological conditions caused by micro-circulatory deficiency in the labyrinth; dizziness; Menierov vertiginozni syndrome and related conditions.

MICROSER 8 mg. 50 tablets

 
 
Symptomatic treatment of pathological conditions caused by micro-circulatory deficiency in the labyrinth; dizziness; Menierov vertiginozni syndrome and related conditions.


2 Dosage and method of administration
2-4 tablets daily, preferably with a meal.

3 Contraindications
Hypersensitivity to the active substance or to any of the excipients. Stomach ulcer in active phase. Pheochromocytoma. Usually contraindicated in pregnancy.

4 Special warnings and precautions for use
In patients with a history of ulcers of the stomach, in order to avoid deterioration in the pathology and in individuals with asthma, MICROSER to be used under medical supervision. Do not use on children.


5 Drug interactions and other forms of interaction
Do not use concurrently with antihistamines.


6 Pregnancy and lactation
In pregnant women the drug be used only in case of extreme need and under direct medical supervision. Before starting treatment with Mikrozer during lactation, seek the advice of a doctor.


7 Effects on ability to drive and use machines
Using MICROSER does not affect the ability to drive and use machines.


8 Adverse reactions
The frequency of adverse reactions are defined as follows:
Very common:> 1/10
Common:> 1/100, <1/10
Uncommon:> 1/1000, <1/100
Rare:> 1/10, 000, <1/1000
Very rare: <1/10 000

Sometimes nausea, headache and signs of idiosyncrasy. (Unspecified frequency)


9 Overdose
No evidence of overdose. In case of overdose, gastric lavage is recommended and appropriate general medical measures. There is no specific antidote for betahistinov dihydrochloride (betahistine didihydrochloride).


10 Pharmacodynamics

Pharmacotherapeutic group: Drugs to treat vertigo ATC code: N07CA01

Betahistinov dihydrochloride was originally synthesized product impact on the microcirculation of organs and helps to restore the micro-circulation flow. This action occurs at the level of the maze. Changes in capillary permeability, modification of blood pressure and influence on the smooth muscle or on gastric acid secretion were observed. Betahistinov histamine dihydrochloride product and act as histamine on the precapillary sphincters, precapillary increasing the microcirculatory flow. Animal studies show that betahistinov dihydrochloride qualitatively act as histamine, but differs from the latter in that it can be administered orally and does not cause side effects of histamine.


11 Pharmacokinetics
In humans, the product is rapidly absorbed after oral administration, reaching peak blood levels until the third hour. The majority of the orally administered dose is excreted in the urine as metabolite: 2-pyridil acetic acid, such complete elimination is achieved in 24 hours.


12 Preclinical safety data
Preclinical safety data in humans based on conventional studies of pharmacology, safety, toxicity, repeated dose, genotoxicity, carcinogenicity and reproductive toxicity studies showed no risk.


List of excipients
Tablets: microcrystalline cellulose; mannitol; silica; talc; citric acid.


Special precautions for storage
Due to the stability of the product MICROSER does not require any special storage conditions
 
 
€ 15.00
Add to Cart
Close